Johnson & Johnson (JNJ) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total Reported Sales | 25.31B | FY2026-Q2 |
| Reported Sales from Innovative Medicine | 16.38B | FY2026-Q2 |
| Reported Sales from MedTech | 8.93B | FY2026-Q2 |
| Reported Sales (International) | 10.78B | FY2026-Q2 |
| Reported Sales in the United States | 14.53B | FY2026-Q2 |
| Johnson and Johnson Adjusted Diluted Earnings Per Share (Non-GAAP) | 2.70 USD_per_share | FY2026-Q1 |
| Adjusted Operational Sales Growth | 5.30 percent | FY2026-Q1 |
| Operational Sales Growth | 6.40 percent | FY2026-Q1 |
| Johnson and Johnson Adjusted Net Earnings (Non-GAAP) | 6.61B | FY2026-Q1 |
| Johnson and Johnson Net Earnings (GAAP) | 5.24B | FY2026-Q1 |
| Reported Sales Growth | 9.90 percent | FY2026-Q1 |
| Johnson and Johnson Free Cash Flow | 1.5B | FY2026-Q1 |
Back to JNJ overview · JNJ earnings · JNJ holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.